This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revision | |||
home:othertreatments:eye_medications [07.14.2011] – [Corticosteroids] paulalbert | home:othertreatments:eye_medications [09.14.2022] (current) – external edit 127.0.0.1 | ||
---|---|---|---|
Line 34: | Line 34: | ||
Patients should work with their doctor or ophthalmologist to limit their use of substances which affect the proper functioning of the immune system. Patients' | Patients should work with their doctor or ophthalmologist to limit their use of substances which affect the proper functioning of the immune system. Patients' | ||
- | Be advised that use of steroids delays resolution of original disease symptoms while on the MP, and can have serious side effects. These side effects include glaucoma, | + | Be advised that use of steroids delays resolution of original disease symptoms while on the MP, and can have serious side effects. These side effects include glaucoma, |
< | < | ||
Although newer corticosteroids with lesser pressure elevating characteristics have been developed, corticosteroid-induced ocular hypertension and glaucoma continue to be significant risks of local and systemic administration. | Although newer corticosteroids with lesser pressure elevating characteristics have been developed, corticosteroid-induced ocular hypertension and glaucoma continue to be significant risks of local and systemic administration. | ||
- | // | + | // |
When possible, physicians should try weaning their patients from immunosuppressive eye drops. Try going down one drop a day. Regular use of olmesartan as per the MP guidelines can help a patient [[home: | When possible, physicians should try weaning their patients from immunosuppressive eye drops. Try going down one drop a day. Regular use of olmesartan as per the MP guidelines can help a patient [[home: | ||
Line 69: | Line 69: | ||
< | < | ||
- | I use [[http:// | + | I use [[https:// |
// | // | ||
Line 84: | Line 84: | ||
{{tag> | {{tag> | ||
+ | < | ||
===== Notes and comments ===== | ===== Notes and comments ===== | ||
- | EDIT | + | |
* Legacy content | * Legacy content | ||
- | * http:// | + | * https:// |
+ | |||
+ | ===== References =====</ | ||
- | ===== References ===== |